Kary Mullis, the Nobel prize-winning inventor of PCR, has entered into a new joint venture with Loxbridge Research to form Altermune Technologies, which will focus on developing therapeutics for pathogens such as methicillin-resistant Staphylococcus aureus, Clostridium difficile, pseudomonas, and pandemic influenza.
Mullis will take on the role of chief scientific officer of Altermune. Charles Roberts, CEO of Loxbridge, will serve as president of Altermune during the initial development period. Loxbridge will provide milestone-based seed funding worth $7 million to Altermune.
Altermune's technology will revolve around the idea of programmable immunity, which involves re-tasking antibodies that are ubiquitous in all humans, present at a high background level, and are ordinarily not tasked by the body in fighting infections. The company will use proprietary linker molecules to redirect these antibodies to selected pathogens.
PrimeraDx said today that Albert Luderer has been appointed to its board of directors.
Luderer currently serves as CEO and a board member at Integrated Diagnostics. Luderer's past roles include: president, CEO, and director at BioTrove, which was acquired by Life Technologies; CEO and director of Light Sciences; president and COO at BioMérieux; and vice president of R&D and business development at Dianon Systems (now Lab Corp).
He has also served as vice president of technology development and support at Boehringer Mannheim (now Roche); and head of biomedical research for Ciba Corning.
Luderer holds a PhD from Rutgers University.